Next generation CD137/4-1BB agonistic monoclonal antibody
LVGN6051 is designed to stimulate the proliferation and cytotoxicity of antitumor immune cells. Optimal efficacy and safety profile are achieved by the crosslinking dependent CD137 agonistic activity through FcγRIIB.
Next generation CD40 agonistic monoclonal antibody
CD40 activation by LVGN7409 promotes tumor antigen presentation and induction of cancer-fighting T cells, and "warm up" the immune-"cold" tumor microenvironment. Unique structure and functionality of LVGN7409 permits its higher tolerable dosage and broader clinical utility.
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.